Tessellate BIO

We’ll be in Stockholm 4-6 November for the 30th Informa Connect EBD Group #BioEurope so get in touch to meet up and find out how we are redefining Synthetic Lethality in cancer beyond homologous recombination deficiency (#HRD). Our CEO Andree Blaukat, CSO Jürgen Moll, PhD and BD Lara Boyd look forward to a busy schedule of panels and presentations and networking with partners and investors. With over 5,500 attendees, representing more than 2,800 companies from over 60 countries it will be busy! We will be delighted to talk about our approach to identifying novel targets to treat cancers in a selective manner, using a combination of dedicated diagnostic assays and proprietary targets. We are building an innovative pipeline by exploiting synthetic lethal targets in DNA damage response (#DDR) pathways and loss-of-function (#LoF) of tumor suppressors. Our lead program targets Alternative Lengthening of Telomeres (#ALT) through the FANCM protein complex. Contact us via the partneringONE system or by email info@tessellatebio.com Visit our new website at www.tessellateBIO.com for further information. #Networking #PrecisonOncology #SyntheticLethality #DrugDiscovery #Biotech 

Our CEO Andree Blaukat and CSO Jürgen Moll, PhD will be in Barcelona next week 23-25 October at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Hosted by the EORTC - European Organisation for Research and Treatment of Cancer (#EORTC), the National Cancer Institute (NCI) (#NCI) and the American Association for Cancer Research (#AACR), the 2024 Symposium attracts academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology. We look forward to sharing updates on how we are redefining Synthetic Lethality in cancer beyond homologous recombination deficiency (#HRD). Our approach is to identify novel targets to treat cancers in a selective manner, using a combination of dedicated diagnostic assays and proprietary targets. We are building an innovative pipeline by exploiting synthetic lethal targets in DNA damage response (#DDR) pathways and loss-of-function (#LoF) of tumor suppressors. Our lead program targets Alternative Lengthening of Telomeres (#ALT) through the FANCM protein complex. To meet us at the EORTC-NCI-AACR Symposium or contact us by email info@tessellatebio.com Visit our new website at www.tessellateBIO.com for further information. #Networking #PrecisonOncology #SyntheticLethality #DrugDiscovery #Biotech 

Tessellate BIO Senior Scientist SALVINA LAURA TAMMACCARO is attending the 4th Exploring DNA Repair Pathways as Targets for Cancer Therapy Conference by Fusion Conferences. Reach out to Salvina to discuss the targets in DDR and synthetic lethality!

Some of the Tessellate Team are attending ELRIG UK Drug Discovery 2024 in London. Great event as always, say hi if you see us! #drugdiscovery Jana Wolf Freddie Grogono Luca Zampieri Ganesh Kadamur Patrick von MorgenIsabella Garcia

This week several members of our R&D team will be attending ELRIG UK 18th Drug Discovery meeting, Drug Discovery 2024. This year’s theme of “Connecting Minds, Transforming Science, Empowering the Community” encourages all to collaborate and work together to tackle the challenges of maintaining health and wellbeing. The conference brings together the drug discovery life science community to learn, network and be inspired. As one of the Conference Directors our head of discovery biology Katie Chapman has been responsible for bringing together an exciting two-day event – ELRIG’s biggest event to date! On Day 1 17.00-18.00 in the Learning Zone, as part of the Early Career Professionals initiative, our molecular pharmacology team lead Ganesh Kadamur will be supporting the networking session as a ‘Network like a boss’ host, sharing information on the biotech, tips to the top and strategies to help with career progression. Drop by to learn from a pro! Visit https://lnkd.in/efG83NSF to view the agenda and for further information. To meet us at #drugdiscovery24 contact us by email info@tessellatebio.com We are happy to share our progress in identifying novel targets to treat cancers in a selective manner, using a combination of dedicated diagnostic assays and proprietary targets. We are building an innovative pipeline by exploiting synthetic lethal targets in DNA damage response (#DDR) pathways and loss-of-function (#LoF) of tumor suppressors. Our lead program targets Alternative Lengthening of Telomeres (#ALT) through the FANCM protein complex. Visit our new website www.tessellatebio.com #elrigdd24 #elrig #PrecisonOncology #SyntheticLethality #DrugDiscovery #Biotech 

COLLABORATION NEWS We are proud to share the news of our collaboration with CMRI Children's Medical Research Institute, a leading Australian pediatric medical research institute, and Omico, an organization uniting over 50 world-class cancer institutes in Australia and New Zealand. The collaboration builds on the existing work of our co-founder Prof. Hilda Pickett at CMRI. It has been established to advance the understanding of the prevalence of alternative lengthening of telomeres (#ALT) across tumor types and the genetic factors involved, and to thereby accelerate the development of precision medicine tools and new cancer therapies. ALT is a mechanism that some cancer cells use to maintain the integrity of their telomeres during cell division and is essential for their unlimited replicative potential. We are developing novel therapies specifically targeting ALT cancers and this collaboration contributes to our leadership position in the field of ALT biology and drug discovery. Our CSO Jürgen Moll, PhD said: “The Omico - CMRI collaboration is instrumental for us to identify subpopulations of patients in different cancer indications that are driven by ALT and for which we are developing targeted drugs. In addition, we are excited about the opportunity to validate the C-Circle Assay to detect ALT+ cancer patients by screening a wide range of human cancer samples. This brings us closer to our aim: to make the C-Circle Assay the future gold standard for identifying these patients in the clinic – true precision medicine.” Read the press release on our new website here https://lnkd.in/eFU9fgjS #collaboration #appointment #PrecisonOncology #syntheticlethality #drugdiscovery #ukbiotech

On World Cancer Research Day, we join with others at the forefront of research into new treatments for cancer to raise awareness of the importance of cancer research in improving the lives of people living with cancer. The vision of our company is to become a global leader in precision oncology by redefining Synthetic Lethality to develop new first in class medicines against novel, validated oncology targets, turning a broader class of cancer patients into cancer survivors. We are developing precision medicines that target unexplored or difficult to drug pathways exploring Synthetic Lethality beyond Homologous Recombination Deficiency (#HRD). Our lead program targets complexes that regulate the Alternative lengthening of telomeres (#ALT) mechanism. We celebrate the dedicated contribution of our team and our work with our academic partners at CMRI Children's Medical Research Institute and Instituto de Medicina Molecular in driving innovation. Cancer is the second leading cause of death worldwide. Together, we can change that. Discover more about our pioneering science at www.tessellatebio.com #WorldCancerResearchDay #WCRD24 #oncology #drugdiscovery #syntheticlethal  

Great to see the article entitled 'The promise of synthetic lethality in precision oncology' by our head of discovery biology Katie Chapman and CSO Jürgen Moll, PhD is now out in Drug Discovery World. 📖 See pages 32-34 to read about our alterative approaches to synthetic lethality to target cancer cells that use alternative lengthening of telomeres #ALT. #drugdiscover #cancer #precisiononcology #innovation Thanks Reece Armstrong

Our CEO Andree Blaukat, CSO Jürgen Moll, PhD and Head of Diagnostics, Joris Schuurmans will be in Barcelona at ESMO - European Society for Medical Oncology to hear about latest developments in oncology and to share how we are redefining Synthetic Lethality in cancer beyond homologous recombination deficiency (#HRD). Our approach is to identify novel targets to treat cancers in a selective manner, using a combination of dedicated diagnostic assays and proprietary targets. We are building an innovative pipeline by exploiting synthetic lethal targets in DNA damage response (#DDR) pathways and loss-of-function (#LoF) of tumor suppressors. Our lead program targets Alternative Lengthening of Telomeres (#ALT) through the FANCM protein complex. To meet us at ESMO or contact us by email info@tessellatebio.com Visit our website at www.tessellateBIO.com for further information. #ESMO24 #PrecisonOncology #SyntheticLethality #DrugDiscovery #Biotech 

We are looking forward to tonight’s Business Weekly newspaper Awards presentation dinner at Queens' College, Cambridge. Our Head of Medicinal Chemistry, Laurent Rigoreau looks forward to networking with other finalists, sponsors and colleagues from across the East of England region. We are delighted to be finalist and in the running for an award. Now in its their 34th year, the awards cover companies across the East of England region in any sector – so competition is fierce! During the last year we have expanded, opening the doors to our labs in Stevenage Bioscience Catalyst and making significant progress in our aim to become a global leader in precision oncology based on a novel approach to the development of highly targeted treatments for cancer. We are redefining Synthetic Lethality to develop treatments for large, currently unserved patient populations. Good luck to all finalists and if you are attending, see you tonight. #awards #drugdiscovery #syntheticlethality #ukbiotech #lifesciences